SCHEMBL964192

SCHEMBL964192

CN(C)OC(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4641763 0.75
SCHEMBL1401727 0.72 KDM6B (0.43)
SCHEMBL4018720 0.72 KDM6B (0.43)
SCHEMBL29180353 0.71
SCHEMBL11517514 0.71
SCHEMBL28325720 0.69
SCHEMBL156391 0.69
SCHEMBL8499931 0.67
SCHEMBL743846 0.67
SCHEMBL19286875 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111793060-A NLRP3 modulators 先天肿瘤免疫公司 2020-10-20 CN disclosed
EP-1871772-B1 QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE INC (US) 2014-09-10 EP disclosed
US-8003664-B2 Indazole-carboxamide compounds THERAVANCE, INC. (US) 2011-08-23 US disclosed
US-7875629-B2 minimal side effects, improved selectivity, potency, pharmacokinetics, and/or duration of action; 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[3-(4-methanesulfonylpiperazine-1-sulfonyl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide; reduced motility of the gastrointestinal tract THERAVANCE, INC. (US) 2011-01-25 US disclosed
US-7851467-B2 Carbamate compounds as 5-HT4 receptor agonists THERAVANCE, INC. (US) 2010-12-14 US disclosed
US-20100292223-A1 INDAZOLE-CARBOXAMIDE COMPOUNDS THERAVANCE, INC. (US) 2010-11-18 US disclosed
US-7786136-B2 Indazole-carboxamide compounds THERAVANCE, INC. (US) 2010-08-31 US disclosed
EP-1831211-B1 INDAZOLE-CARBOXAMIDE COMPOUNDS THERAVANCE INC (US) 2010-06-02 EP disclosed
EP-1960396-B1 CARBAMATE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE INC (US) 2009-11-11 EP disclosed
EP-1807422-B1 5-HT4 RECEPTOR AGONIST COMPOUNDS THERAVANCE INC (US) 2009-09-02 EP disclosed
US-20060135764-A1 Indazole-carboxamide compounds THERAVANCE, INC. 2006-06-22 US disclosed
WO-2006052640-A1 5-HT4 RECEPTOR AGONIST COMPOUNDS THERAVANCE, INC. (US) 2006-05-18 WO disclosed
WO-2006052889-A2 QUINOLINONE-CARBOXAMIDE COMPOUNDS THERAVANCE, INC. (US) 2006-05-18 WO disclosed
US-20060100236-A1 For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome THERAVANCE, INC. (US) 2006-05-11 US disclosed
US-20060100426-A1 Quinolinone-carboxamide compounds THERAVANCE, INC. 2006-05-11 US disclosed
US-5886175-A TETRACYCLINE ANTIBIOTICS AMERICAN CYANAMID COMPANY (US) 1999-03-23 US disclosed
US-5512553-A PREVENTING OR TREATING BACTERIAL INFECTIONS AMERICAN CYANAMID COMPANY (US) 1996-04-30 US disclosed
US-5495018-A ANTIBIOTIC INTERMEDIATES AMERICAN CYANAMID COMPANY (US) 1996-02-27 US disclosed
US-5430162-A Tetracycline antibiotics AMERICAN CYANAMID COMPANY (US) 1995-07-04 US disclosed
EP-0582810-A1 Novel 7-(substituted)-8-(substituted)-9-(substituted amino)-6-demethyl-6-deoxyetracyclines as antibiotic agents AMERICAN CYANAMID COMPANY (US) 1994-02-16 EP disclosed